OpenAI acquires biotech startup Orchestra Bio to push into drug development
Photo: Crypto Briefing
The ChatGPT maker is folding Orchestra's agent-driven drug program platform into its Rosalind life sciences suite OpenAI is buying its way into one of the slowest industries on Earth. On October 20, 2026, the company announced it has acquired Orchestra Bio, a startup that uses AI to streamline how biopharma teams develop drugs. Moving a drug from discovery to market in the US can take anywhere from 10 to 15 years. Orchestra Bio built a platform that lets humans and AI agents jointly manage drug programs.
Source: Crypto Briefing
